다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
iscience, v.23 no.8, 2020년, pp.101411 -
Li, Zhichao (Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China) , Qian, Youhui (Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China) , Li, Wujiao (Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China) , Liu, Lisa (Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China) , Yu, Lei (Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China) , Liu, Xia (Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China) , Wu, Guodong (Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China) , Wang, Youyu (Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China) , Luo, Weibin , Fang, Fuyuan , Liu, Yuchen , Song, Fei , Cai, Zhiming , Chen, Wei , Huang, Weiren
AI-Helper
SummaryLung cancer is an extremely heterogeneous disease, and its treatment remains one of the most challenging tasks in medicine. Few existing laboratory lung cancer models can faithfully recapitulate the diversity of the disease and predict therapy response. Here, we establish 12 patient-derived o...
Boj S.F. Hwang C.I. Baker L.A. Chio II Engle D.D. Corbo V. Jager M. Ponz-Sarvise M. Tiriac H. Spector M.S. Organoid models of human and mouse ductal pancreatic cancer Cell 160 2015 324 338 25557080
Broutier L. Mastrogiovanni G. Verstegen M.M. Francies H.E. Gavarro L.M. Bradshaw C.R. Allen G.E. Arnes-Benito R. Sidorova O. Gaspersz M.P. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening Nat. Med. 23 2017 1424 1435 29131160
Camidge D.R. Bang Y.J. Kwak E.L. Iafrate A.J. Varella-Garcia M. Fox S.B. Riely G.J. Solomon B. Ou S.H. Kim D.W. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol. 13 2012 1011 1019 22954507
Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550 25079552
Desai T.J. Brownfield D.G. Krasnow M.A. Alveolar progenitor and stem cells in lung development, renewal and cancer Nature 507 2014 190 194 24499815
Devesa S.S. Bray F. Vizcaino A.P. Parkin D.M. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising Int. J. Cancer 117 2005 294 299 15900604
Eguchi T. Kadota K. Park B.J. Travis W.D. Jones D.R. Adusumilli P.S. The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know Semin. Thorac. Cardiovasc. Surg. 26 2014 210 222 25527015
Fatima N. Cohen C. Lawson D. Siddiqui M.T. TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks Cancer Cytopathol. 119 2011 127 133 21287692
Ferlay J. Soerjomataram I. Dikshit R. Eser S. Mathers C. Rebelo M. Parkin D.M. Forman D. Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int. J. Cancer 136 2015 E359 E386 25220842
Gao D. Vela I. Sboner A. Iaquinta P.J. Karthaus W.R. Gopalan A. Dowling C. Wanjala J.N. Undvall E.A. Arora V.K. Organoid cultures derived from patients with advanced prostate cancer Cell 159 2014 176 187 25201530
Gurda G.T. Zhang L. Wang Y. Chen L. Geddes S. Cho W.C. Askin F. Gabrielson E. Li Q.K. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases Clin. Transl. Med. 4 2015 16 25977750
Herbst R.S. Heymach J.V. Lippman S.M. Lung cancer N.？Engl. J. Med. 359 2008 1367 1380 18815398
Hirsch F.R. Scagliotti G.V. Mulshine J.L. Kwon R. Curran W.J. Jr. Wu Y.L. Paz-Ares L. Lung cancer: current therapies and new targeted treatments Lancet 389 2017 299 311 27574741
Imielinski M. Berger Alice H. Hammerman Peter S. Hernandez B. Pugh Trevor J. Hodis E. Cho J. Suh J. Capelletti M. Sivachenko A. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 2012 1107 1120 22980975
Janne P.A. Yang J.C. Kim D.W. Planchard D. Ohe Y. Ramalingam S.S. Ahn M.J. Kim S.W. Su W.C. Horn L. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N.？Engl. J. Med. 372 2015 1689 1699 25923549
Jordan E.J. Kim H.R. Arcila M.E. Barron D. Chakravarty D. Gao J. Chang M.T. Ni A. Kundra R. Jonsson P. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies Cancer Discov. 7 2017 596 609 28336552
Kim C.F. Jackson E.L. Woolfenden A.E. Lawrence S. Babar I. Vogel S. Crowley D. Bronson R.T. Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer Cell 121 2005 823 835 15960971
Kim M. Mun H. Sung C.O. Cho E.J. Jeon H.J. Chun S.M. Jung D.J. Shin T.H. Jeong G.S. Kim D.K. Patient-derived lung cancer organoids as in？vitro cancer models for therapeutic screening Nat. Commun. 10 2019 3991 31488816
Lee S.H. Hu W. Matulay J.T. Silva M.V. Owczarek T.B. Kim K. Chua C.W. Barlow L.J. Kandoth C. Williams A.B. Tumor evolution and drug response in patient-derived organoid models of bladder cancer Cell 173 2018 515 528.e517 29625057
Lemjabbar-Alaoui H. Hassan O.U. Yang Y.W. Buchanan P. Lung cancer: biology and treatment options Biochim. Biophys. Acta 1856 2015 189 210 26297204
Li X. Francies H.E. Secrier M. Perner J. Miremadi A. Galeano-Dalmau N. Barendt W.J. Letchford L. Leyden G.M. Goffin E.K. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics Nat. Commun. 9 2018 2983 30061675
Li Y.F. Gao Y. Liang B.W. Cao X.Q. Sun Z.J. Yu J.H. Liu Z.D. Han Y. Patient-derived organoids of non-small cells lung cancer and their application for drug screening Neoplasma 67 2020 430 437 31973535
Mengoli M.C. Longo F.R. Fraggetta F. Cavazza A. Dubini A. Ali G. Guddo F. Gilioli E. Bogina G. Nannini N. The 2015 World Health Organization classification of lung tumors: new entities since the 2004 classification Pathologica 110 2018 39 67 30259912
Molina J.R. Yang P. Cassivi S.D. Schild S.E. Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clinic Proc. 83 2008 584 594
Morgan K.M. Riedlinger G.M. Rosenfeld J. Ganesan S. Pine S.R. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine Front. Oncol. 7 2017 2 28154808
Moro M. Bertolini G. Tortoreto M. Pastorino U. Sozzi G. Roz L. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells J.？Biomed. Biotechnol. 2012 2012 568567 22547927
Ou S.H. Ahn J.S. De Petris L. Govindan R. Yang J.C. Hughes B. Lena H. Moro-Sibilot D. Bearz A. Ramirez S.V. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study J.？Clin. Oncol. 34 2016 661 668 26598747
Patel M.I. Cheng I. Gomez S.L. US lung cancer trends by histologic type Cancer 121 2015 1150 1152
Sachs N. de Ligt J. Kopper O. Gogola E. Bounova G. Weeber F. Balgobind A.V. Wind K. Gracanin A. Begthel H. A living biobank of breast cancer organoids captures disease heterogeneity Cell 172 2018 373 386.e310 29224780
Sachs N. Papaspyropoulos A. Zomer-van Ommen D.D. Heo I. Bottinger L. Klay D. Weeber F. Huelsz-Prince G. Iakobachvili N. Amatngalim G.D. Long-term expanding human airway organoids for disease modeling EMBO J. 38 2019 e100300
Shaw A.T. Kim D.W. Nakagawa K. Seto T. Crino L. Ahn M.J. De Pas T. Besse B. Solomon B.J. Blackhall F. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N.？Engl. J. Med. 368 2013 2385 2394 23724913
Shi R. Radulovich N. Ng C. Liu N. Notsuda H. Cabanero M. Martins-Filho S.N. Raghavan V. Li Q. Mer A.S. Organoid cultures as preclinical models of non-small cell lung cancer Clin. Cancer Res. 26 2020 1162 1174 31694835
Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2018 CA A Cancer J. Clin. 68 2018 7 30
Spella M. Lilis I. Pepe M.A. Chen Y. Armaka M. Lamort A.S. Zazara D.E. Roumelioti F. Vreka M. Kanellakis N.I. Club cells form lung adenocarcinomas and maintain the alveoli of adult mice eLife 8 2019 e45571
Suzuki A. Matsushima K. Makinoshima H. Sugano S. Kohno T. Tsuchihara K. Suzuki Y. Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment Genome Biol. 16 2015 66 25887790
Tatsumori T. Tsuta K. Masai K. Kinno T. Taniyama T. Yoshida A. Suzuki K. Tsuda H. p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2 Appl. Immunohistochem. Mol. Morphol. 22 2014 377 382 24805133
Travis W.D. Rekhtman N. Riley G.J. Geisinger K.R. Asamura H. Brambilla E. Garg K. Hirsch F.R. Noguchi M. Powell C.A. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift J.？Thorac. Oncol. 5 2010 411 414 20357614
Travis W.D. Brambilla E. Riely G.J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials J.？Clin. Oncol. 31 2013 992 1001 23401443
Vassilev L.T. Vu B.T. Graves B. Carvajal D. Podlaski F. Filipovic Z. Kong N. Kammlott U. Lukacs C. Klein C. In？vivo activation of the P53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848 14704432
Vlachogiannis G. Hedayat S. Vatsiou A. Jamin Y. Fernandez-Mateos J. Khan K. Lampis A. Eason K. Huntingford I. Burke R. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers Science 359 2018 920 926 29472484
Wang J. Li X. Chen H. Organoid models in lung regeneration and cancer Cancer Lett. 475 2020 129 135 32032677
van de Wetering M. Francies H.E. Francis J.M. Bounova G. Iorio F. Pronk A. van Houdt W. van Gorp J. Taylor-Weiner A. Kester L. Prospective derivation of a living organoid biobank of colorectal cancer patients Cell 161 2015 933 945 25957691
Xu X. Rock J.R. Lu Y. Futtner C. Schwab B. Guinney J. Hogan B.L. Onaitis M.W. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma Proc. Natl. Acad. Sci. U S A 109 2012 4910 4915 22411819
Yan H.H.N. Siu H.C. Law S. Ho S.L. Yue S.S.K. Tsui W.Y. Chan D. Chan A.S. Ma S. Lam K.O. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening Cell Stem Cell 23 2018 882 897.e11 30344100
Yang J.C. Sequist L.V. Geater S.L. Tsai C.M. Mok T.S. Schuler M. Yamamoto N. Yu C.J. Ou S.H. Zhou C. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Lancet Oncol. 16 2015 830 838 26051236
Yin H. Jiang Z. Feng X. Ji Z. Jin W. Identification of Sca-1(+)Abcg1(+) bronchioalveolar epithelial cells as the origin of lung adenocarcinoma in Gprc5a-knockout mouse model through the interaction between lung progenitor AT2 and Lgr5 cells Oncogene 39 2020 3754 3773 32157214
Zappa C. Mousa S.A. Non-small cell lung cancer: current treatment and future advances Transl. Lung Cancer Res. 5 2016 288 300 27413711
Zhang D.G. Jiang A.G. Lu H.Y. Zhang L.X. Gao X.Y. Isolation, cultivation and identification of human lung adenocarcinoma stem cells Oncol. Lett. 9 2015 47 54 25435932
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.